Key Takeaways
- The DEA cannabis rescheduling hearing today is not legalization; it considers moving marijuana from Schedule I to Schedule III.
- Schedule III would recognize medical use but keeps cannabis federally controlled, without fixing banking, clearing records, or ensuring adult-use protection.
- The hearing is part of a rulemaking process; outcomes may not be clear immediately, and operators should be cautious with headlines.
- Small operators may face consolidation risks even if Schedule III offers tax relief, as large companies might benefit more.
- The process needs to prioritize the voices of those impacted by cannabis prohibition, ensuring fair representation for small businesses and legacy operators.
NORTH AMERICA – The DEA’s long-awaited marijuana rescheduling hearing starts today, and the cannabis industry is once again being told to hold its breath while the federal government decides what to do with a plant that millions of Americans already use legally under state law.
Let’s be clear from the jump.This isn’t legalization or descheduling. It’s also not an admission from the federal government that the War on Drugs was a policy failure that wrecked lives, crushed families, and handed criminal records to people for doing what corporations are now lining up to profit from.
This is a hearing about whether marijuana should move from Schedule I to Schedule III under the Controlled Substances Act. That matters. The move could change tax treatment, reshape research, and unlock new financial pathways, giving some operators relief from 280E. However, it might also create a cleaner runway for large medical cannabis companies, pharmaceutical interests, institutional investors, and compliance-heavy operators. This would leave adult-use businesses, small brands, legacy operators, social equity licensees, and mom-and-pop shops stuck in the same federal gray zone they have been surviving in for years.
For small operators, the question is not just whether Schedule III happens. The question is whether federal reform becomes a lifeline, or the starting gun for the next wave of consolidation.
So yes, this hearing matters. But anyone pretending this is a simple victory lap is selling a fantasy with a compliance binder stapled to it.
What Is Actually Happening Today?
The Drug Enforcement Administration is opening formal administrative hearing proceedings on the proposed marijuana rescheduling from Schedule I to Schedule III. The proceeding follows years of pressure, scientific review, political messaging, public comment, bureaucratic delay, and enough federal tap dancing to make your head spin.
Schedule I is supposed to mean a substance has no currently accepted medical use and a high potential for abuse. That classification has been absurd for decades. Patients, physicians, researchers, caregivers, veterans, cancer survivors, people managing chronic pain, and state medical cannabis programs have already proven that cannabis has medical value in real life, not just in federal paperwork.
Schedule III would be a major shift. It would place cannabis in a category that recognizes accepted medical use, but still keeps it federally controlled. That means cannabis would remain illegal outside federally approved channels. Rescheduling cannabis wouldn’t automatically protect adult-use markets or fix banking issues. It also wouldn’t clear records, stop federal interference, or instantly transform cannabis businesses into “normal” businesses overnight.
That is the part too many headlines leave out. Schedule III is not freedom. It is a different cage with better tax treatment for some.
How the DEA Hearing Process Works
Today’s hearing is not a final vote, and nobody should expect cannabis to wake up tomorrow fully legalized, normalized, or free from federal uncertainty. This is part of the administrative rulemaking process, which means the DEA is taking formal testimony, building a record, and moving toward a final decision on whether marijuana should be transferred from Schedule I to Schedule III.
That distinction matters. A hearing is a step in the process, not the end of the process.
The proceeding is being handled through the DEA’s formal hearing structure, with an administrative law judge overseeing arguments, testimony, procedural issues, and the evidentiary record. After the hearing concludes, the record can inform the agency’s final rulemaking decision. That means the real outcome may not be clear immediately, and operators should be careful about treating headlines as final policy.
Why the Hearing Matters (and What it Won’t Do)
The most important thing to understand is that the hearing does not equal legalization. Schedule III would still leave marijuana inside the Controlled Substances Act. It could create meaningful tax and research consequences, especially around 280E, but it would not automatically deschedule cannabis, erase criminal records, legalize interstate commerce, protect every adult-use operator, or solve the federal-state conflict overnight.
It also matters who gets to participate. If pro-cannabis organizations, reform advocates, small operators, patients, prisoners, and legacy voices are not meaningfully represented in the room, then the hearing record risks becoming another federal document about cannabis that does not fully reflect the people most affected by cannabis prohibition or the businesses that carried legalization this far.
That is why the industry should watch this process closely. Not just for what the DEA says about science or scheduling, but for what the process reveals about federal priorities. Who gets heard in the market? Which individuals are ignored? Who receives protection, and which people are positioned for the next phase?
Because in cannabis, process is never just process. It is often where the winners and losers get quietly chosen.
Why 280E Is the Big Financial Story
For cannabis operators, the biggest immediate reason rescheduling matters is Section 280E of the federal tax code. Under 280E, businesses trafficking in Schedule I or Schedule II substances cannot deduct ordinary business expenses the way normal businesses can. Rent, payroll, marketing, insurance, security, legal fees, accounting, and basic operating costs all become part of a brutal tax reality.
That has crushed cannabis businesses for years. Licensed operators pay taxes like they are printing money while many are barely surviving. They operate under state law, pay state licensing fees, follow seed-to-sale tracking rules, submit to inspections, hire locally, support communities, and still get treated like criminals when federal tax time rolls around.
If cannabis moves broadly to Schedule III, 280E should no longer apply in the same way. That could free up cash flow, improve profitability, make financing more realistic, and give operators breathing room they should have had years ago.
But here is where the skepticism comes in. Who actually gets that relief? Medical operators? Adult-use operators? Vertically integrated giants? State-licensed dispensaries? Small cultivators? Equity operators? Ancillary companies? Brands without direct plant-touching licenses?
The answer matters, because tax relief can either stabilize the industry or accelerate consolidation.
If Schedule III becomes a tool that mostly benefits the biggest, cleanest, best-capitalized companies while everyone else waits for guidance, litigation, or new federal rules, then this is not reform. It is a restructuring of the industry under federal permission.
For Small Operators, Schedule III Could Be Relief or a Trap
For small cannabis operators, Schedule III is not just a policy debate. It is a survival question.
The industry has spent years talking about 280E relief like it is a magic switch. And yes, ending the 280E burden for state-licensed cannabis businesses would be massive. For small operators, it could mean hiring staff instead of cutting hours. It could mean paying vendors on time. It could mean reinvesting in cultivation, retail, manufacturing, marketing, compliance, and community instead of watching federal tax bills eat the business alive.
But tax relief alone does not guarantee fairness.
A small operator still has to survive licensing fees, local taxes, state excise taxes, testing costs, insurance, payroll, debt, rent, price compression, limited shelf space, predatory financing, and competition from companies with deeper pockets and better access to capital. If Schedule III triggers a rush of institutional investment, mergers, acquisitions, and federally preferred medical or pharmaceutical pathways, small businesses may find themselves technically helped by reform while practically squeezed even harder.
Tax Relief Isn’t a Silver Bullet
That is the part Washington needs to understand. A tax change can help small operators breathe, but it can also make them more attractive acquisition targets. It can invite new capital into the space, but that capital may not flow to family-owned farms, independent retailers, equity licensees, craft brands, or legacy operators trying to transition into the legal market. It may flow to whoever already has the lawyers, accountants, lobbyists, balance sheets, and corporate polish to look “safe” on paper.
Small operators do not need federal reform that turns them into chum for consolidation. They need reform that recognizes who actually built this industry and gives them a fair shot to remain in it.
That means clarity on 280E. This means access to banking and fair tax treatment. There should be no new federal framework that only large operators can afford to navigate. Adult-use operators cannot be treated like second-class citizens while pharmaceutical interests get the cleanest lane forward. And it means legacy operators and social equity businesses cannot be used as talking points while policy is written for companies that showed up after the risk started looking profitable.
If Schedule III is going to matter, it has to matter beyond the boardroom.
Small Businesses Built This Industry
Before cannabis was a public-market pitch deck, before MSOs had investor calls, before pharmaceutical lobbyists started sniffing around cannabinoids, before federal agencies discovered the phrase “accepted medical use,” small operators built this industry.
Patients built it. Caregivers built it. Legacy growers built it. Medical collectives built it. Activists built it. Families of prisoners built it. Underground cultivators who risked their freedom built it. Small dispensary owners built it. Local brands built it. Budtenders built consumer education one conversation at a time. Writers, advocates, nurses, veterans, attorneys, accountants, and community organizers kept the pressure alive when Washington would not even say the word cannabis without acting like it needed a shower afterward.
Now the federal government is stepping into a marketplace that already exists and acting like it gets to decide who counts.
That is the danger. Rescheduling could become a backdoor handoff. Not from prohibition to justice, but from prohibition to pharmaceutical control. From legacy culture to corporate gatekeeping. From state-legal small business to federally blessed winners and losers.
If the government wants to do the right thing, it needs to center the people who carried this plant through criminalization. It needs to protect small businesses, repair communities, free cannabis prisoners, support social equity operators, respect state adult-use systems, and prevent federal reform from becoming a corporate land grab.
Instead, much of the process still feels like cannabis reform is being discussed around the industry, not with it.
Adult-Use Cannabis Still Does Not Fit Cleanly Inside Schedule III
This is where things get messy, and cannabis operators need to pay attention.
Schedule III is a medical drug framework. Adult-use cannabis is not a prescription drug market. It is a state-regulated consumer market. That does not mean it is unserious or unsafe. In many states, adult-use cannabis is more tracked, tested, labeled, restricted, and monitored than plenty of products sitting on shelves in mainstream retail.
But federal law does not have a clean box for state-legal adult-use cannabis under Schedule III.
That is the trap.
A medical-only Schedule III framework could help certain medical cannabis businesses, research programs, and future FDA-approved cannabinoid drugs while leaving adult-use operators in limbo. That could create a two-tier industry where federally favored medical and pharmaceutical channels get legitimacy, while adult-use markets remain exposed.
For California, Massachusetts, Missouri, New York, Michigan, Illinois, Nevada, Colorado, Oregon, Washington, and every other adult-use state, that distinction is not some academic debate. It affects tax planning, licensing value, investment, banking risk, interstate commerce, enforcement priorities, and long-term survival.
The cannabis industry should not accept a federal reform model that treats adult-use markets like an inconvenient side effect. Adult-use legalization is where much of the modern cannabis economy lives. It is also where many equity programs, small businesses, craft operators, and legacy transition pathways exist.
Ignoring adult-use means ignoring the actual industry.
What Operators Should Watch During the Hearing
The most important thing to watch is not whether federal officials say cannabis has medical value. That should have been obvious long ago. The more important question is how narrowly or broadly the government tries to define the benefits of Schedule III.
Operators should watch for any discussion around whether state-licensed adult-use businesses can access 280E relief if marijuana moves to Schedule III. They should watch how the DEA frames state cannabis programs, whether medical cannabis is treated differently from adult-use cannabis, and whether the process creates new federal registration expectations that only larger companies can realistically satisfy.
They should also pay attention to how much weight is given to public health concerns without equal attention to prohibition harms. Cannabis policy cannot be judged only by theoretical risks of use while ignoring the real damage caused by arrests, incarceration, loss of housing, loss of employment, family separation, and decades of discriminatory enforcement.
Another key issue is research. Schedule III may make research easier, but research reform should not become an excuse to slow down broader justice. We do not need another decade of federal agencies pretending they just discovered patients exist.
Finally, operators should watch the market reaction. Investors may treat Schedule III as a signal. Lenders may start reevaluating risk. Larger companies may prepare acquisitions. Smaller companies may get pitched “strategic opportunities” that are really just lowball consolidation plays dressed up in nicer shoes.
The Government Has Not Earned Blind Trust
The cannabis community has every right to be skeptical. The same federal government that spent decades criminalizing cannabis now wants applause for possibly moving it to Schedule III. That is progress, but it is not redemption.
People are still in prison for cannabis. Families continue to carry the weight of past convictions. Operators are still blocked from capital because they followed state law in an industry the federal government refuses to normalize. Legacy growers often cannot afford licensing. Small brands find themselves squeezed by taxes, compliance costs, retail slotting games, debt, and corporate competition.
So when federal officials talk about rescheduling, the industry should ask a simple question: reform for whom?
If Schedule III helps patients, supports research, removes 280E from state-legal operators, and creates a bridge toward broader legalization, good. Take the win and keep pushing.
But if Schedule III becomes a narrow medical carveout that mostly benefits pharmaceutical companies, large operators, and institutional capital while leaving adult-use cannabis and legacy small businesses exposed, then we need to call it what it is: federal cannabis reform with velvet ropes.
This Is a “What to Watch” Moment, Not a Victory Lap
Today’s DEA hearing is one of the biggest federal cannabis events on the calendar, but it should be treated as a checkpoint, not a finish line.
Operators should watch for language that signals who gets tax relief, who gets recognized, who gets excluded, and who gets set up for the next phase of consolidation. Advocates should watch for whether social justice is treated as central or ignored entirely. Patients should watch for whether access expands or becomes more medicalized and expensive. Adult-use businesses should watch for whether the government even knows what to do with them.
Because the uncomfortable truth is this: cannabis legalization was not built by the federal government. It was built despite the federal government.
The people who risked everything to normalize this plant should not be shoved aside now that cannabis is finally becoming federally useful to investors, pharmaceutical companies, and political campaigns looking for easy reform points.
Schedule III may be a step forward. But it is not enough. We can’t move forward without small businesses. There must be clarity on adult use and relief for prisoners. Expungement is essential, and we must include legacy operators. Above all, we cannot forget the communities that paid the highest price for prohibition.
The DEA hearing starts today. Cannabis reform is in the room.
Now the question is whether the people who built this industry are allowed in, or whether they are about to watch another closed-door policy process decide their future without them.
Frequently Asked Questions
The hearing is a formal administrative proceeding to consider moving marijuana from Schedule I to Schedule III under the Controlled Substances Act. It is part of the rulemaking process, not a final vote, and it does not legalize cannabis.
No. Schedule III would recognize accepted medical use, but cannabis would remain federally controlled and illegal outside federally approved channels. It does not protect adult-use markets, fix banking, clear criminal records, or legalize interstate commerce.
If marijuana moves broadly to Schedule III, the 280E tax penalty that blocks cannabis businesses from deducting ordinary expenses should no longer apply in the same way. This could improve cash flow and profitability, though it remains unclear exactly which operators would benefit.
Rescheduling moves cannabis to a less restrictive category (Schedule III) while keeping it inside the Controlled Substances Act. Descheduling would remove cannabis from the Act entirely, treating it more like alcohol or tobacco. This hearing only concerns rescheduling.
The hearing builds an evidentiary record that informs the agency’s final rulemaking decision. The outcome may not be clear immediately, so operators should avoid treating headlines as final policy.
